750
Participants
Start Date
February 5, 2014
Primary Completion Date
January 31, 2027
Study Completion Date
January 31, 2027
Viral specific VST Infusion
"VSTs will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the below:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \>1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies.~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy.~* Evidence of PML or other CNS infection due to JC virus."
RECRUITING
Akron Children's Hospital, Akron
COMPLETED
University of Cincinnati Medical Center, Cincinnati
RECRUITING
Cincinnati Children's Hospital Medical Center, Cincinnati
Hoxworth Blood Center
OTHER
Children's Hospital Medical Center, Cincinnati
OTHER